Analyse Eli Lilly stock

Plausibly confirmed.
Reason: The consensus price target of 1105.54 EUR is only around +4.2% above the current price of 1060.96 EUR and is therefore clearly within the required ±25% range.
Quantitative: Eli Lilly is trading despite its high valuation a P/E ratio of 33.45, which is still justifiable for a rapidly growing pharmaceutical/biotech profile; The extreme price performance from the 52W low of 545.18 EUR to near the 52W high of 1082.01 EUR shows strong momentum and revaluation effects. The small upside signals that a large part of the expected profit growth has already been priced in. Compared to its peers, Lil...